Mirae Asset Global Investments Co. Ltd. Sells 127 Shares of argenx SE (NASDAQ:ARGX)

Mirae Asset Global Investments Co. Ltd. lowered its position in shares of argenx SE (NASDAQ:ARGX) by 3.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 3,285 shares of the company’s stock after selling 127 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in argenx were worth $2,044,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in the company. FMR LLC increased its position in argenx by 35.9% during the 3rd quarter. FMR LLC now owns 4,793,472 shares of the company’s stock worth $2,598,445,000 after buying an additional 1,265,486 shares during the period. Janus Henderson Group PLC grew its stake in shares of argenx by 0.4% in the third quarter. Janus Henderson Group PLC now owns 2,479,207 shares of the company’s stock valued at $1,343,797,000 after acquiring an additional 10,975 shares in the last quarter. Wellington Management Group LLP increased its position in argenx by 13.0% during the third quarter. Wellington Management Group LLP now owns 482,346 shares of the company’s stock worth $261,470,000 after acquiring an additional 55,617 shares during the period. Alkeon Capital Management LLC raised its stake in argenx by 15.0% in the 3rd quarter. Alkeon Capital Management LLC now owns 345,000 shares of the company’s stock worth $187,018,000 after purchasing an additional 45,000 shares in the last quarter. Finally, Jennison Associates LLC boosted its holdings in argenx by 27.0% in the 4th quarter. Jennison Associates LLC now owns 302,149 shares of the company’s stock valued at $185,821,000 after purchasing an additional 64,183 shares during the period. 60.32% of the stock is owned by institutional investors and hedge funds.

argenx Stock Down 0.0 %

Shares of ARGX stock opened at $646.45 on Tuesday. The firm has a market capitalization of $39.28 billion, a P/E ratio of -734.60 and a beta of 0.58. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The stock’s fifty day simple moving average is $637.69 and its 200 day simple moving average is $578.86.

Analysts Set New Price Targets

ARGX has been the topic of several recent research reports. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 target price (up from $646.00) on shares of argenx in a report on Thursday, November 21st. Baird R W lowered argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Wedbush reiterated an “outperform” rating and set a $655.00 target price on shares of argenx in a research report on Tuesday, December 3rd. Scotiabank upgraded argenx from a “sector perform” rating to a “sector outperform” rating and raised their price target for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Finally, Piper Sandler upped their price objective on shares of argenx from $620.00 to $725.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $658.39.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.